Denali-Sanofi's ALS drug fails to meet main goal of mid-stage trial
Denali Therapeutics said on Friday it was informed by partner Sanofi that their drug for a type of neurological disease did not meet the main goal in a mid-stage trial.
Sanofi Q4 earnings burdened by weak dollar, generic competition
Sanofi's fourth-quarter operating income declined 5% as a weaker U.S. dollar and cheaper rivals competing against its established multiple sclerosis drug outweighed growing sales of anti-inflammato...
Sanofi To Acquire Inhibrx in $1.7 Billion Deal To Boost Rare Disease Drugs Pipeline
Inhibrx (INBX) shares jumped over 7% in early trading Tuesday after Sanofi (SNY) said it would buy Inhibrx in a $1.7 billion deal as the French pharmaceutical giant expands its pipeline of drugs to...
Sanofi to Buy Rare-Disease Assets From Inhibrx
Sanofi plans to buy assets from U.S. biopharmaceutical company Inhibrx in a deal valued at up to $2.2 billion.
France's Sanofi to buy U.S. drugs project INBRX-101 for about $2.2 bln
French healthcare company Sanofi has agreed to buy the drug development project INBRX-101 from its parent company Inhibrx Inc for around $2.2 billion, the companies said on Tuesday.
Drugs group Sanofi makes Olympic jump in rebrand bid
Sanofi is hoping that by sponsoring the Olympic Games it can attract new talent, reward existing staff and shake off the French drugmaker's conservative image.
Sanofi (SNY) Presents at J.P. Morgan 42nd Annual Healthcare Conference Call Transcript
Sanofi (SNY) Presents at J.P. Morgan 42nd Annual Healthcare Conference Call Transcript
Here's Why Sanofi (SNY) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
FTC vs Big Pharma: Sanofi drops Maze deal
The Federal Trade Commission has been scrutinizing Big Pharma deals, finally scoring a win with Sanofi (SNY) scrapping its proposed licensing deal with Maze Therapeutics. The FTC said it would seek...
Sanofi ends licensing deal with Maze Therapeutics after FTC action
Sanofi SA SAN, +1.94% said late Monday it will scuttle an agreement with biotech Maze Therapeutics Inc. after federal trade regulators sought to block it, saying the deal would eliminate competitio...
Sanofi terminates deal on drug license after US FTC objects
Sanofi said on Monday it was terminating a deal to exclusively license a drug that Maze Therapeutics is developing to treat Pompe disease because of objections from the U.S. government.
Sanofi (SNY) Posts Upbeat Long-Term Outlook, Enhances R&D Focus
Sanofi (SNY) aims to generate annual sales of over 10 billion euros by 2030, driven by recently launched and potential new products. It intends to enhance R&D focus to become a market leader in imm...
Sanofi to boost drug development spend by 700 mln euros in 2024
Sanofi said it would spend close to 700 million euros ($754 million) more on drugs development next year, specifying for the first time an increase in costs that roiled investors and triggered a se...
Sanofi to focus on 12 blockbuster drug candidates, immunology pipeline
Sanofi said on Thursday it will focus on 12 potential blockbuster drug candidates and prioritise development in immunology, as it faces investor pressure after abandoning 2025 margin targets while ...
Related Companies